JBS N.V. Class A Common Shares vs Koninklijke Philips NV — how do they compare? JBS N.V. Class A Common Shares trades at $13 (market cap $13.86B), while Koninklijke Philips NV trades at $24.98 (market cap $24.24B). The key difference: Koninklijke Philips NV is the larger of the two by market cap, and JBS N.V. Class A Common Shares pays the higher dividend (10.38%). Which is the better fit depends on your goals — on Pluang, investors hold JBS N.V. Class A Common Shares for 0 Days and Koninklijke Philips NV for 84 Days on average.
| JBS | PHG | |
|---|---|---|
Market Cap | $13.86B | $24.24B |
Volume | 4,980,049 | 982,766 |
Sector | Consumer Staples | Health |
52-Week High | $18.42 | $32.91 |
52-Week Low | $10.86 | $23.81 |
Typical Hold Time | 0 Days | 84 Days |
Enterprise Value | $34.83B | $30.57B |
Dividend Yield | 10.38% | 4.07% |
Signals from Pluang's Aura AI — not financial advice
JBS trades at $12.93, up 0.54% today, with a neutral technical signal and strong analyst buy consensus. The stock shows attractive valuation with a P/E of 12.08 and P/S of 0.47, though recent quarterly EPS misses and a declining profit margin to 1.22% in 2026 highlight earnings pressure. Recent news includes a proposal to acquire full control of Pilgrim's Pride and a joint venture in Southeast Asia, indicating strategic expansion.
The outlook is mixed: analyst targets suggest ~40% upside to $18.17, but risks include execution on acquisitions, margin compression, and volatile beef markets. Cash flow turned positive in 2026 projections, supporting growth initiatives, yet debt levels and competitive pressures warrant caution for investors seeking stability.
PHG trades at $25.00, up 1.05% today, with a bullish technical signal despite mixed oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $0.57 exceeding the $0.40 estimate. Revenue for 2025 was $17.83 billion, with a net income margin of 5.01%, showing a recovery from prior losses. Recent news highlights product launches and strategic partnerships in healthcare technology.
The outlook is cautiously optimistic, supported by earnings momentum and innovation, but risks include competitive pressures and debt levels. Analysts are mixed, with a 'Hold' consensus, while institutional buying activity indicates underlying confidence. Valuation metrics like a P/E of 19.49 suggest the stock is fairly priced relative to peers.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
JBS N.V. is a protein-processing company producing beef, pork, poultry, lamb, fish, and plant-based products, headquartered in São Paulo and Amsterdam. It operates more than 250 production facilities across over 16 countries under brands including Friboi, Seara, Swift, and Pilgrim's, and is the majority shareholder of Pilgrim's Pride Corporation.
Read more on JBS →Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →